Across TCGA pan-cancer cohorts, FAM166B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM166B data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher FAM166B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM166B expression acts as an unfavorable survival marker.

SKCM and UCEC are the cancer types where FAM166B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.169	0.692	.001	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: FAM166B tumor-vs-normal RNA expression · all FAM166B data types